Tissue repair peptides — including BPC-157 and TB-500 — have generated significant interest among patients recovering from musculoskeletal injuries, surgical procedures, and chronic inflammatory conditions. The mechanism is well-characterized: these peptides upregulate growth factors involved in tissue regeneration and modulate inflammatory pathways. At Diversity Healthcare, we evaluate patients for tissue repair peptide therapy based on injury type, chronicity, and response to conventional treatment. Patients who have not achieved expected recovery through standard rehabilitation are often the best candidates.